Targeting blood stem cell activity and extramedullary monocytopoiesis to treat atherosclerosis

靶向血液干细胞活性和髓外单核细胞生成治疗动脉粥样硬化

基本信息

项目摘要

Monocytes adhere and infiltrate the vascular bed in the early stages of atherosclerosis. Once they have entered the vascular wall they differentiate into macrophages, which are known to amplify vascular inflammation. While many pro-inflammatory features of macrophages are already known (e.g. the role of the inflammasome, diminished efferocytosis, impaired netrin-1 dependent emigration), surprisingly little is known about the supply of these cells. Particularly under inflammatory conditions, hematopoietic stem and progenitor cells are released from the bone marrow and seed the spleen, where they give rise to myeloid progenitor cells (GMP and MDP), which then give rise to pro-inflammatory monocytes. Interestingly, myocardial infarction induces the release of hematopoietic stem and progenitor cells from the bone marrow with consecutively increased extramedullary monocytopoiesis, which in turn further aggravates vascular inflammation. While the bone marrow niche has been intensively studied in the last few years, the so-called splenic hematopoietic niche remains poorly understood. However, especially splenic hematopoiesis is a hallmark for many chronic inflammatory processes and leads to the generation of monocytes. Own preliminary work indicates that particularly splenic endothelial cells are crucially involved in the regulation of extramedullary monocytopoiesis. Inhibition of an endothelial adhesion molecule (e-selectin) reduces proliferation rates of hematopoietic stem and progenitor cells in the spleen and is accompanied by profound athero-protective effects in an animal model of atherosclerosis (ApoE-/-). The next step will be to decipher the interaction between splenic endothelial cells and hematopoietic stem and progenitor cells; specifically, we will investigate whether differentiation and proliferation of myeloid progenitor cells as well as an altered release of proliferative cytokines from splenic endothelial cells may be responsible for the observed effects. Further, we will image hematopoietic stem and progenitor cells in the spleen and analyze their anatomical localization in the context of chronic inflammatory base line conditions. To this end, we will use different transgenic mouse models (e.g. endothelial specific knockout mice), transplantation model of murine spleens, and various other cellular and molecular technologies, including imaging methods, such as FMT/CT. Splenic endothelial cells will be FAC-sorted. The overall aim of this application is to shed light on the poorly characterized, splenic hematopoietic niche in order to develop a treatment strategy to combat vascular inflammation.
单核细胞在动脉粥样硬化的早期粘附并浸润血管床。一旦它们进入血管壁,它们就会分化成巨噬细胞,巨噬细胞会放大血管炎症。虽然巨噬细胞的许多促炎特征是已知的(例如炎性小体的作用、减少的细胞增多症、受损的netrin-1依赖性迁移),但令人惊讶的是,对这些细胞的供应知之甚少。特别是在炎症条件下,造血干细胞和祖细胞从骨髓释放并接种脾脏,在那里它们产生骨髓祖细胞(GMP和MDP),然后产生促炎单核细胞。有趣的是,心肌梗死诱导造血干细胞和祖细胞从骨髓中释放,髓外单核细胞生成持续增加,这反过来又进一步加剧了血管炎症。虽然骨髓生态位在过去几年中得到了深入研究,但所谓的脾造血生态位仍然知之甚少。然而,特别是脾造血是许多慢性炎症过程的标志,并导致单核细胞的产生。自己的初步工作表明,特别是脾内皮细胞是至关重要的参与调节髓外单核细胞生成。在动脉粥样硬化动物模型(ApoE-/-)中,内皮粘附分子(e-选择素)的抑制降低了脾脏中造血干细胞和祖细胞的增殖率,并伴随着显著的动脉粥样硬化保护作用。下一步将是破译脾内皮细胞和造血干细胞和祖细胞之间的相互作用,具体来说,我们将调查是否分化和骨髓祖细胞的增殖以及从脾内皮细胞增殖细胞因子的释放改变可能是负责观察到的效果。此外,我们还将对脾脏中的造血干细胞和祖细胞进行成像,并分析其在慢性炎症基线条件下的解剖定位。为此,我们将使用不同的转基因小鼠模型(例如内皮特异性敲除小鼠),小鼠脾脏移植模型,以及各种其他细胞和分子技术,包括成像方法,如FMT/CT。将对脾内皮细胞进行FAC-sorted。本申请的总体目的是阐明表征不佳的脾造血生态位,以开发对抗血管炎症的治疗策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Privatdozent Dr. Friedrich Felix Hoyer其他文献

Privatdozent Dr. Friedrich Felix Hoyer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Privatdozent Dr. Friedrich Felix Hoyer', 18)}}的其他基金

The impact of infectious disease on cardiovascular leukocyte heterogeneity in mice
传染病对小鼠心血管白细胞异质性的影响
  • 批准号:
    448821529
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
    Research Grants
The Role of Adaptive and Innate Immunity for the Development of Aortic Valve Stenosis
适应性和先天免疫在主动脉瓣狭窄发展中的作用
  • 批准号:
    535107899
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
    Research Grants

相似国自然基金

基于MFSD2A调控血迷路屏障跨细胞囊泡转运机制的噪声性听力损失防治研究
  • 批准号:
    82371144
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
内源性蛋白酶抑制剂SerpinA3N对缺血性脑卒中后血脑屏障的保护作用及其表达调控机制
  • 批准号:
    82371317
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
KLK10调控胶质—血管耦合与对话促缺血性卒中后血脑屏障修复的机制
  • 批准号:
    82371465
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
骨骼肌中胰高血糖素受体的表达及其调控血糖稳态的作用与机制研究
  • 批准号:
    82370820
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
气体信号分子硫化氢对颈动脉窦压力反射感受器的调节作用及机制
  • 批准号:
    81100181
  • 批准年份:
    2011
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
精神分裂症特异微小RNA的筛选、鉴定及其靶向调控功能研究
  • 批准号:
    81000583
  • 批准年份:
    2010
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
人脐血间充质干细胞成骨潜能亚群的特异性分子标志
  • 批准号:
    30800232
  • 批准年份:
    2008
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Targeting Trained Immunity in Trauma-Induced Immune Dysregulation
针对创伤引起的免疫失调中训练有素的免疫力
  • 批准号:
    10714384
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Therapeutic Targeting of WDR5 in the Glioblastoma Perivascular Niche
WDR5 在胶质母细胞瘤血管周围微环境中的治疗靶向
  • 批准号:
    10581400
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Targeting bone marrow to treat renal disease
靶向骨髓治疗肾脏疾病
  • 批准号:
    10584343
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Targeting trained immunity in transplantation
在移植中瞄准经过训练的免疫力
  • 批准号:
    10642592
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
BCCMA: Targeting Osteoarthritis Pain and Progression: Defining biologic and inflammatory markers associated with rapid progression
BCCMA:针对骨关节炎疼痛和进展:定义与快速进展相关的生物和炎症标志物
  • 批准号:
    10486497
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
An IGF-1R-targeting peptide drug conjugate for targeted treatment of atypical teratoid/rhabdoid tumors
用于靶向治疗非典型畸胎瘤/横纹肌样瘤的 IGF-1R 靶向肽药物缀合物
  • 批准号:
    10760549
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Targeting of IL-1 Signaling in Myelofibrosis
骨髓纤维化中 IL-1 信号传导的靶向
  • 批准号:
    10657996
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Targeting PRC1 in leukemia
靶向 PRC1 治疗白血病
  • 批准号:
    10712963
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Therapeutic targeting of the SWI/SNF chromatin remodeler to regulate GBM chemosensitivity
SWI/SNF 染色质重塑剂的治疗靶向调节 GBM 化学敏感性
  • 批准号:
    10711581
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Targeting CD83 to reduce leukemia relapse and GVHD after allogeneic hematopoietic cell transplantation
靶向CD83减少同种异体造血细胞移植后白血病复发和GVHD
  • 批准号:
    10573570
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了